Alnylam completes enrollment in another late-stage study of lumasiran in rare kidney disorder

• Alnylam Pharmaceuticals (NASDAQ:ALNY) has completed the enrollment of 21 subjects in a Phase 3 clinical trial, ILLUMINATE-C, evaluating RNAi therapeutic lumasiran in patients with advanced primary hyperoxaluria type 1 (PH1), a rare disorder caused by the buildup of oxalate, normally filtered through the kidneys and excreted in urine, that leads to kidney and bladder stones.
• The primary endpoints are the percent change in plasma oxalate from baseline to month 6 and the percent change in pre-dialysis plasma oxalate from baseline to month 6.
• Lumasiran, branded as Oxlumo, was approved in the U.S. and Europe last month for the treatment of all age groups with PH1.